Cushing's Syndrome Therapeutics Pipeline Analysis - Collaboration, and Other Developments


Posted August 2, 2017 by Prajneesh

The expending growth of pipeline for Cushing’s syndrome therapeutics is attributed to the increase in prevalence of inflammatory disorders.

 
In many diseases such as asthma and rheumatoid arthritis, corticosteroids are being used, for a lifelong period but at low doses. However, when the disease fails to respond to lower doses of corticosteroids, the dose needs to be increased. The pipeline for Cushing’s syndrome is majorly driven by factors such as, increasing healthcare awareness in patients and the occurrence of abnormal growth of cells in pituitary gland which can further lead to the formation of tumour.

[b]Explore Report at:[/b] https://www.psmarketresearch.com/market-analysis/cushing-syndrome-therapeutics-pipeline-analysis

Cushing’s syndrome is a condition that occurs when a person is exposed to the hormone cortisol at a very high level, for a longer period of time, this is sometimes called as hypercortisolism. It mostly affects obese people at the aged between 20 to 50 years, who have type 2 diabetes and high blood pressure. The symptoms of the Cushing’s syndrome, include, round face, upper body obesity, deposition of fat around neck and relatively lean arms and legs. In some cases, skin of the patients become fragile, heals poorly, bruises easily and purple or pink marks appear on the abdomen, buttocks, thigh and breast. Bones become weakened and spinal and column fracture can occur when person is doing any routine activity like bending, lifting etc. Other symptoms include severe fatigue, increased thirst and urination, irritability, anxiety, depression and weak muscles.

[b]Request for Table of Content at:[/b] https://www.psmarketresearch.com/market-analysis/cushing-syndrome-therapeutics-pipeline-analysis/toc-sample

In April 2012, Strongbridge Biopharma Plc was in the process of collaboration with Moulder Center Drug Discovery for the development of new therapies of cortisol modulation for Cushing syndrome therapeutics. In July 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. announced that the companies are undergoing a strategic immuno-oncology collaboration in Japan, South Korea and Taiwan, which includes the development and commercialization of immune mediated endocrinopathies. In September 2008, Corcept Therapeutics and Eli Lilly and Company announced that the companies would continue the collaboration for testing the effectiveness of GRII receptor antagonist in rat models of olanzapine induced weight gain.

Some of the companies having a pipeline of Cushing’s syndrome therapeutics include Corcept Therapeutics, Millendo Therapeutics, Inc., Strongbridge Biopharma Plc, Novartis AG. Ono Pharmaceutical Co., Ltd. Bristol-Myers Squibb Company.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By P&S Market Research
Business Address New York
Country United States
Categories Business , Health , Medical
Tags cushings syndrome therapeutics , cushings syndrome therapeutics pipeline , cushings syndrome therapeutics pipeline analysis , cushings syndrome therapeutics pipeline report
Last Updated August 2, 2017